CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
PremiumPress ReleasesCG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
2M ago
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
PremiumPress Releases
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
2M ago
CG Oncology upgraded to Buy from Neutral at Goldman Sachs
PremiumThe Fly
CG Oncology upgraded to Buy from Neutral at Goldman Sachs
2M ago
3 Best Stocks to Buy Now, 5/7/2024, According to Top Analysts 
PremiumMarket News3 Best Stocks to Buy Now, 5/7/2024, According to Top Analysts 
3M ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
3M ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
3M ago
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
PremiumPress ReleasesCG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
4M ago
Five new option listings and one option delisting on March 12th
PremiumThe Fly
Five new option listings and one option delisting on March 12th
5M ago
CG Oncology announces first patient dosed in PIVOT-006 Phase 3 trial
PremiumThe Fly
CG Oncology announces first patient dosed in PIVOT-006 Phase 3 trial
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100